{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:59:43Z","timestamp":1790794783884,"version":"4.1.0"},"reference-count":219,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Around 77 new oncology drugs were approved by the FDA in the past five years; however, most cancers remain untreated. Small molecules and antibodies are dominant therapeutic modalities in oncology. Antibody-drug conjugates, bispecific antibodies, peptides, cell, and gene-therapies are emerging to address the unmet patient need. Advancement in the discovery and development platforms, identification of novel targets, and emergence of new technologies have greatly expanded the treatment options for patients. Here, we provide an overview of various therapeutic modalities and the current treatment options in oncology, and an in-depth discussion of the therapeutics in the preclinical stage for the treatment of breast cancer, lung cancer, and multiple myeloma.<\/jats:p>","DOI":"10.3390\/ijms22042008","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T20:56:21Z","timestamp":1613681781000},"page":"2008","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Therapeutic Advances in Oncology"],"prefix":"10.3390","volume":"22","author":[{"given":"Jinsha","family":"Liu","sequence":"first","affiliation":[{"name":"Protein Engineering, Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Pandya","sequence":"additional","affiliation":[{"name":"Protein Engineering, Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Afshar","sequence":"additional","affiliation":[{"name":"Protein Engineering, Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"key":"ref_1","unstructured":"American Cancer Society (ACS) (2018). Global Cancer Facts & Figures, American Cancer Society. Available online: www.cancer.org."},{"key":"ref_2","unstructured":"IQVIA (2019, May 30). Global Oncology Trends 2019. Therapeutics, Clinical Development and Health System Implications. Available online: www.iqvia.com."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1208\/s12248-019-0402-2","article-title":"The Evolving Druggability and Developability Space: Chemically Modified New Modalities and Emerging Small Molecules","volume":"22","author":"Yang","year":"2020","journal-title":"AAPS J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1021\/acschembio.7b00485","article-title":"Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation","volume":"12","author":"Ottis","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1200\/JCO.2019.37.7_suppl.259","article-title":"ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer","volume":"37","author":"Neklesa","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Flanagan, J.J., Qian, Y., Gough, S.M., Andreoli, M., Bookbinder, M., Cadelina, G., Bradley, J., Rousseau, E., Willard, R., and Pizzano, J. (2019). Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer. Cancer Res., 79.","DOI":"10.1158\/1538-7445.SABCS18-P5-04-18"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Leung, D., Wurst, J.M., Liu, T., Martinez, R.M., Datta-Mannan, A., and Feng, Y. (2020). Antibody Conjugates-Recent Advances and Future Innovations. Antibodies, 9.","DOI":"10.3390\/antib9010002"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: A mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The Therapeutic Potential of Nanobodies","volume":"34","author":"Jovcevska","year":"2020","journal-title":"BioDrugs"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Baliga, R., Li, K., Manlusoc, M., Hinton, P.R., Ng, D.C., Tran, M.H., Shan, B., Lu, H., Saini, A., and Rahman, S. (2020). A Bispecific IgM Antibody Format for Enhanced T cell-Dependent Killing with Minimal Cytokine Release. Cancer Res.","DOI":"10.1158\/1538-7445.AM2020-5664"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic peptides: Historical perspectives, current development trends, and future directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/d41573-020-00099-9","article-title":"Cancer cell therapies: The clinical trial landscape","volume":"19","author":"Yu","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_14","unstructured":"Businesswire (2020, September 01). U.S. FDA Approves Kite\u2019s Tecartus\u2122, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma. Businesswire. Available online: www.businesswire.com."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: A new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1134\/S002689331803010X","article-title":"Oncolytic Paramyxoviruses: Mechanism of Action, Preclinical and Clinical Studies","volume":"52","author":"Matveeva","year":"2018","journal-title":"Mol. Biol. (Mosk.)"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nrd.2016.178","article-title":"Oncolytic viruses: A new class of immunotherapy drugs","volume":"15","author":"Kaufman","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/cco.2018.04.04","article-title":"The emerging role of oncolytic virus therapy against cancer","volume":"7","author":"Russell","year":"2018","journal-title":"Chin. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"10294","DOI":"10.1002\/anie.201611914","article-title":"New Modalities for Challenging Targets in Drug Discovery","volume":"56","author":"Valeur","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1038\/mtna.2016.26","article-title":"Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice","volume":"5","author":"Yu","year":"2016","journal-title":"Mol. Nucleic Acids"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1021\/cb200176v","article-title":"Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA","volume":"6","author":"Ma","year":"2011","journal-title":"ACS Chem. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40169-020-0268-z","article-title":"The clinical potential of gene editing as a tool to engineer cell-based therapeutics","volume":"9","author":"Fruhwirth","year":"2020","journal-title":"Clin. Transl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrg3686","article-title":"A guide to genome engineering with programmable nucleases","volume":"15","author":"Kim","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41592-019-0323-0","article-title":"In vivo RNA editing of point mutations via RNA-guided adenosine deaminases","volume":"16","author":"Katrekar","year":"2019","journal-title":"Nat. Methods"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrm.2015.4","article-title":"A-to-I editing of coding and non-coding RNAs by ADARs","volume":"17","author":"Nishikura","year":"2016","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/d41586-020-00272-5","article-title":"Step aside CRISPR, RNA editing is taking off","volume":"578","author":"Reardon","year":"2020","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1258096","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13046-020-01603-0","article-title":"Description of CRISPR\/Cas9 development and its prospect in hepatocellular carcinoma treatment","volume":"39","author":"Wu","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_30","unstructured":"Stein, R. (2020, September 01). First U.S. Patients Treated with CRISPR as Human Gene-Editing Trials Get Underway. Available online: www.npr.org."},{"key":"ref_31","unstructured":"Henderson, H. (2020, September 01). CRISPR Clinical Trials: A 2019 Update. Innovative Genomics Institute. Available online: innovativegenomics.org."},{"key":"ref_32","unstructured":"Rosenbaum, L. (2020, September 01). New Data from First Human Crispr Trials Shows Promising Results. Available online: www.forbes.com."},{"key":"ref_33","unstructured":"NIH (2020, September 01). CRISPR Based Clinical trials on Clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?term=CRISPR&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&type=&rslt=&Search=Apply."},{"key":"ref_34","unstructured":"NIH (2020, September 01). Cancer Stat Facts: Female Breast Cancer, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000442726","article-title":"Dose-Dense Chemotherapy in Metastatic Breast Cancer: Shortening the Time Interval for a Better Therapeutic Index","volume":"11","author":"Schmidt","year":"2016","journal-title":"Breast Care"},{"key":"ref_36","unstructured":"NIH (2020, September 01). Cancer Stat Facts: Female Breast Cancer Subtypes, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41523-018-0082-6","article-title":"Clinical relevance of the 21-gene Recurrence Score(\u00ae) assay in treatment decisions for patients with node-positive breast cancer in the genomic era","volume":"4","author":"Mamounas","year":"2018","journal-title":"NPJ Breast Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40164-015-0028-8","article-title":"Breast cancer brain metastases: The last frontier","volume":"4","author":"Leone","year":"2015","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.18.01160","article-title":"Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update","volume":"37","author":"Burstein","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/jnci\/djj357","article-title":"Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: Meta-analysis","volume":"98","author":"Mauri","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_42","unstructured":"ACS (2018). Breast Cancer Fact and Figure 2017-2018, ACS. Available online: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/breast-cancer-facts-and-figures\/breast-cancer-facts-and-figures-2017-2018.pdf."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13045-018-0620-6","article-title":"Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer","volume":"11","author":"Spicer","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_44","first-page":"73","article-title":"Everolimus in the Treatment of Metastatic Breast Cancer","volume":"9","author":"Royce","year":"2015","journal-title":"Breast Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.7150\/jca.32628","article-title":"Cyclin-Dependent Kinases 4\/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies","volume":"10","author":"Niu","year":"2019","journal-title":"J. Cancer"},{"key":"ref_46","unstructured":"FDA (2020, August 01). FDA Approves First PI3K Inhibitor for Breast Cancer, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-pi3k-inhibitor-breast-cancer."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1200\/JCO.2019.37.15_suppl.1005","article-title":"Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial","volume":"37","author":"Jones","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S1470-2045(19)30164-0","article-title":"Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Jiang","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_49","unstructured":"ACS Targeted Therapy for Breast Cancer, ACS. Available online: www.cancer.org\/cancer\/breast-cancer\/treatment\/targeted-therapy-for-breast-cancer.html."},{"key":"ref_50","unstructured":"FDA (2020, September 01). FDA Approves Neratinib for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-neratinib-extended-adjuvant-treatment-early-stage-her2-positive-breast-cancer."},{"key":"ref_51","unstructured":"FDA (2020, October 01). FDA Approves Neratinib for Metastatic HER2-Positive Breast Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-neratinib-metastatic-her2-positive-breast-cancer."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2018.05.004","article-title":"Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer","volume":"67","author":"Duchnowska","year":"2018","journal-title":"Cancer Treat Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1200\/JCO.2013.54.0955","article-title":"Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Ramakrishna","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"10030","DOI":"10.1021\/acs.jmedchem.6b00618","article-title":"Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer","volume":"59","author":"Heffron","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_55","unstructured":"FDA (2020, September 01). FDA Approves Tucatinib for Patients with HER2-Positive Metastatic Breast Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancer."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"P2-20-01","DOI":"10.1158\/1538-7445.SABCS19-P2-20-01","article-title":"Abstract P2-20-01: Impact of neratinib on development and progression of central nervous system (CNS) metastases in patients with HER2-positive metastatic breast cancer (MBC): Findings from the NALA, NEfERT-T, and TBCRC 022 trials","volume":"80","author":"Awada","year":"2020","journal-title":"J. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1200\/JCO.18.01511","article-title":"TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2\u2013Positive Breast Cancer and Brain Metastases","volume":"37","author":"Freedman","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2217\/fon.13.7","article-title":"Trastuzumab emtansine: The first targeted chemotherapy for treatment of breast cancer","volume":"9","author":"Peddi","year":"2013","journal-title":"Future Oncol."},{"key":"ref_59","unstructured":"FDA (2020, October 01). FDA Approves Ado-Trastuzumab Emtansine for Early Breast Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ado-trastuzumab-emtansine-early-breast-cancer."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Jerusalem, G., Park, Y.H., Yamashita, T., Hurvitz, S.A., Chen, S., Cathcart, J., Lee, C., and Perrin, C. (2020). 138O CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses. Ann. Oncol.","DOI":"10.1016\/j.annonc.2020.03.239"},{"key":"ref_62","unstructured":"NIH (2020, September 01). DS-8201a in Pre-Treated HER2 Breast Cancer That Cannot Be Surgically Removed or Has Spread [DESTINY-Breast02], Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03523585."},{"key":"ref_63","unstructured":"NIH (2020, October 01). DS-8201a versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and\/or Metastatic Breast Cancer Previously Treated with Trastuzumab and Taxane [DESTINY-Breast03], Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03529110."},{"key":"ref_64","unstructured":"NIH (2020, October 01). Trastuzumab Deruxtecan (DS-8201a) versus Investigator\u2019s Choice for HER2-low Breast Cancer That Has Spread or Cannot Be Surgically Removed [DESTINY-Breast04], Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03734029."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Rinnerthaler, G., Gampenrieder, S.P., and Greil, R. (2019). HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer. Int. J. Mol. Sci., 20.","DOI":"10.20944\/preprints201902.0043.v1"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"R2","DOI":"10.1186\/bcr1843","article-title":"Cytogenetic analysis of HER1\/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients","volume":"10","author":"Sassen","year":"2008","journal-title":"Breast Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1158\/1535-7163.MCT-19-1004","article-title":"ARX788, a Site-specific Anti-HER2 Antibody\u2014Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1\u2013resistant Breast and Gastric Cancers","volume":"19","author":"Skidmore","year":"2020","journal-title":"J. Mol. Cancer Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1200\/JCO.2018.36.15_suppl.1014","article-title":"A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer","volume":"36","author":"Saura","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"P1-18-16","DOI":"10.1158\/1538-7445.SABCS19-P1-18-16","article-title":"Abstract P1-18-16: A phase 1 study of ARX788, a HER2-targeting antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer","volume":"80","author":"Hu","year":"2020","journal-title":"J. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"PD1-03-PD01-03","DOI":"10.1158\/1538-7445.SABCS18-PD1-03","article-title":"Abstract PD1-03: Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results of a phase 1\/2 trial","volume":"79","author":"Masuda","year":"2019","journal-title":"J. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Rugo, H.S., Im, S.-A., Cardoso, F., Cortes, J., Curigliano, G., Pegram, M.D., Musolino, A., Bachelot, T., Wright, G.S., and De Laurentiis, M. (2020). Abstract GS1-02: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: Second interim overall survival analysis. J. Cancer Res., 80.","DOI":"10.1158\/1538-7445.SABCS19-GS1-02"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/PPO.0b013e3181d24ff7","article-title":"Triple-negative breast cancer: Role of specific chemotherapy agents","volume":"16","author":"Isakoff","year":"2010","journal-title":"Cancer J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1517\/14728222.2016.1125469","article-title":"Triple negative breast cancer chemosensitivity and chemoresistance: Current advances in biomarkers indentification","volume":"20","author":"Guestini","year":"2016","journal-title":"Expert Opin. Targets"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000455820","article-title":"Biological Subtypes of Triple-Negative Breast Cancer","volume":"12","author":"Hubalek","year":"2017","journal-title":"Breast Care"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nature10933","article-title":"The clonal and mutational evolution spectrum of primary triple-negative breast cancers","volume":"486","author":"Shah","year":"2012","journal-title":"Nature"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.2014.59.0018","article-title":"Inhibition of the PI3K\/AKT\/mTOR Pathway in Solid Tumors","volume":"34","author":"LoRusso","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_78","unstructured":"NIH (2020, October 01). A Study of Ipatasertib in Combination with Paclitaxel as a Treatment for Participants with PIK3CA\/AKT1\/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130); NIH: 2020, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03337724."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"CT049","DOI":"10.1158\/1538-7445.AM2019-CT049","article-title":"Abstract CT049: Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced\/metastatic triple-negative breast cancer (TNBC)","volume":"79","author":"Schmid","year":"2019","journal-title":"Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41571-019-0322-1","article-title":"AKT inhibition improves OS in TNBC","volume":"17","author":"Killock","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12672-015-0232-3","article-title":"Androgen Receptor Biology in Triple Negative Breast Cancer: A Case for Classification as AR+ or Quadruple Negative Disease","volume":"6","author":"Barton","year":"2015","journal-title":"Horm. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","article-title":"Enzalutamide for the Treatment of Androgen Receptor\u2014Expressing Triple-Negative Breast Cancer","volume":"36","author":"Traina","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.clbc.2015.11.003","article-title":"Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients","volume":"16","author":"Tan","year":"2016","journal-title":"Clin. Breast Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.2147\/OTT.S126051","article-title":"Targeting the androgen receptor in triple-negative breast cancer: Current perspectives","volume":"10","author":"Mina","year":"2017","journal-title":"Oncol. Targets"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"OT1-02","DOI":"10.1158\/1538-7445.SABCS18-OT1-02-01","article-title":"Abstract OT1-02-01: Phase I trial of bicalutamide and ribociclib in androgen receptor-positive triple negative breast cancer","volume":"79","author":"Sharifi","year":"2019","journal-title":"J. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"P5-05","DOI":"10.1158\/1538-7445.SABCS18-P5-05-05","article-title":"Abstract P5-05-05: Targeting the androgen receptor with seviteronel, a CYP17 lyase and AR inhibitor, in triple negative breast cancer","volume":"79","author":"Reese","year":"2019","journal-title":"J. Cancer Res."},{"key":"ref_88","first-page":"1827","article-title":"Increased Tumour Infiltration of CD4+ and CD8+ T-Lymphocytes in Patients with Triple Negative Breast Cancer Suggests Susceptibility to Immune Therapy","volume":"18","author":"Sikandar","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12967-018-1514-7","article-title":"Immunotherapeutic interventions of Triple Negative Breast Cancer","volume":"16","author":"Li","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_90","unstructured":"FDA (2020, October 01). FDA Approves Atezolizumab for PD-L1 Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer; 2019, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1200\/JCO.2020.38.15_suppl.1000","article-title":"KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer","volume":"38","author":"Cortes","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"176","DOI":"10.18632\/genesandcancer.180","article-title":"The promising immune checkpoint LAG-3: From tumor microenvironment to cancer immunotherapy","volume":"9","author":"Long","year":"2018","journal-title":"Genes Cancer"},{"key":"ref_93","unstructured":"FDA (2020, October 01). FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-therapy-triple-negative-breast-cancer-has-spread-not-responded-other-treatments."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Nagayama, A., Vidula, N., Ellisen, L., and Bardia, A. (2020). Novel antibody-drug conjugates for triple negative breast cancer. Adv. Med. Oncol., 12.","DOI":"10.1177\/1758835920915980"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"PD1-06","DOI":"10.1158\/1538-7445.SABCS19-PD1-06","article-title":"Abstract PD1-06: Open label phase 1b\/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer","volume":"80","author":"Han","year":"2020","journal-title":"J. Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"7950","DOI":"10.1038\/s41598-020-64534-y","article-title":"Differential responses to kinase inhibition in FGFR2-addicted triple negative breast cancer cells: A quantitative phosphoproteomics study","volume":"10","author":"Cunningham","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_97","unstructured":"NIH (2020, November 01). Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02393794."},{"key":"ref_98","unstructured":"NIH (2020, November 01). Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer; NIH: 2020, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02453620."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pharmthera.2019.02.006","article-title":"Recent therapeutic trends and promising targets in triple negative breast cancer","volume":"199","author":"Hwang","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_100","unstructured":"NIH (2020, September 01). BRCA Mutations: Cancer Risk and Genetic Testing, Available online: https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/genetics\/brca-fact-sheet#r2."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","article-title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","volume":"29","author":"Cruz","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: Different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875","article-title":"Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases","volume":"24","author":"Morales","year":"2014","journal-title":"Crit. Rev. Eukaryot Gene Expr."},{"key":"ref_104","first-page":"167","article-title":"Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1\/2 Mutation","volume":"10","author":"Caulfield","year":"2019","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_105","unstructured":"NIH (2020, September 01). BRCA Mutation:PARP Inhibitor, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/results?cond=BRCA+breast+cancer&term=olaparib&cntry=&state=&city=&dist=."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Keung, M.Y.T., Wu, Y., and Vadgama, J.V. (2019). PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. J. Clin. Med., 8.","DOI":"10.3390\/jcm8040435"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e1299272","DOI":"10.1080\/23723556.2017.1299272","article-title":"Sensitizing HR-proficient cancers to PARP inhibitors","volume":"4","author":"Lim","year":"2017","journal-title":"Mol. Cell Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1517\/13543784.2012.660249","article-title":"Sapacitabine for cancer","volume":"21","author":"Liu","year":"2012","journal-title":"Expert Opin Investig Drugs."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"CT050","DOI":"10.1158\/1538-7445.AM2019-CT050","article-title":"Abstract CT050: Expansion cohort of Phase I study of oral sapacitabine and oral seliciclib in patients with metastatic breast cancer and BRCA1\/2 mutations","volume":"79","author":"Keenan","year":"2019","journal-title":"J. Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Jette, N.R., Kumar, M., Radhamani, S., Arthur, G., Goutam, S., Yip, S., Kolinsky, M., Williams, G.J., Bose, P., and Lees-Miller, S.P. (2020). ATM-Deficient Cancers Provide New Opportunities for Precision Oncology. Cancers, 12.","DOI":"10.3390\/cancers12030687"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage\u2013Inducing or Repair\u2013Compromising Therapies in Preclinical Cancer Models","volume":"19","author":"Wengner","year":"2020","journal-title":"J. Mol. Cancer Ther."},{"key":"ref_113","unstructured":"ACS (2020, September 01). Key Statistic of Lung Cancer; ACS. Available online: www.cancer.org\/cancer\/lung-cancer\/about\/key-statistics.html."},{"key":"ref_114","unstructured":"ALA (2020, September 01). Lung Cancer Facts Sheet; ALA. Available online: https:\/\/www.lung.org\/lung-health-diseases\/lung-disease-lookup\/lung-cancer\/resource-library."},{"key":"ref_115","unstructured":"ACS (2020, September 01). About Lung Cancer; ACS. Available online: www.cancer.org\/cancer\/lung-cancer\/about\/what-is.html."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"13185","DOI":"10.1038\/s41598-017-13724-2","article-title":"The best platinum regimens for chemo-naive incurable non-small cell lung cancer: Network meta-analysis","volume":"7","author":"Horita","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"15437","DOI":"10.1038\/srep15437","article-title":"Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients","volume":"5","author":"Horita","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_118","first-page":"S565","article-title":"Chemotherapy advances in small-cell lung cancer","volume":"5","author":"Chan","year":"2013","journal-title":"J. Thorac Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41392-019-0099-9","article-title":"The emerging treatment landscape of targeted therapy in non-small-cell lung cancer","volume":"4","author":"Yuan","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_120","unstructured":"FDA (2020, October 01). FDA Approves First Blood Test to Detect Gene Mutation Associated with Non-Small Cell Lung Cancer; FDA: 2016, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-blood-test-detect-gene-mutation-associated-non-small-cell-lung-cancer."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Schulze, A.B., Evers, G., Kerkhoff, A., Mohr, M., Schliemann, C., Berdel, W.E., and Schmidt, L.H. (2019). Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer. Cancers, 11.","DOI":"10.3390\/cancers11050690"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jtho.2019.10.013","article-title":"Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses","volume":"15","author":"Owonikoko","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_123","first-page":"580","article-title":"Recent advances in targeted small-molecule inhibitor therapy for non-small-cell lung cancer\u2014An update","volume":"45","author":"Atal","year":"2020","journal-title":"J. Clin. Pharm."},{"key":"ref_124","unstructured":"FDA (2020, October 01). FDA Approves First Targeted Therapy to Treat Aggressive Form of Lung Cancer; FDA: 2020, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-targeted-therapy-treat-aggressive-form-lung-cancer."},{"key":"ref_125","unstructured":"FDA (2020, October 01). FDA Approves Pralsetinib for Lung Cancer with RET Gene Fusions; FDA: 2020, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions#:~:text=FDA%20approves%20pralsetinib%20for%20lung%20cancer%20with%20RET,(NSCLC)%20as%20detected%20by%20an%20FDA%20approved%20test."},{"key":"ref_126","unstructured":"FDA (2020, September 01). FDA Approves Selpercatinib for Lung and Thyroid Cancers with RET Gene Mutations Or Fusions; FDA: 2020, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions."},{"key":"ref_127","unstructured":"FDA (2020, October 01). FDA Approves Nivolumab Plus Ipilimumab for First-Line mNSCLC (PD-L1 Tumor Expression \u22651%); FDA: 2020, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-nivolumab-plus-ipilimumab-first-line-mnsclc-pd-l1-tumor-expression-1."},{"key":"ref_128","unstructured":"FDA (2020, October 01). FDA Approves Nivolumab Plus Ipilimumab and Chemotherapy for First-Line Treatment of Metastatic NSCLC; FDA: 2020, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-nivolumab-plus-ipilimumab-and-chemotherapy-first-line-treatment-metastatic-nsclc."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_130","unstructured":"FDA (2020, August 01). Pembrolizumab (Keytruda) 5-10-2017. FDA: 2017, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/pembrolizumab-keytruda-5-10-2017."},{"key":"ref_131","unstructured":"FDA (2020, September 01). FDA Approves Atezolizumab with Chemotherapy and Bevacizumab for First-Line Treatment of Metastatic Non-Squamous NSCLC; FDA: 2018, Available online: https:\/\/www.fda.gov\/drugs\/fda-approves-atezolizumab-chemotherapy-and-bevacizumab-first-line-treatment-metastatic-non-squamous."},{"key":"ref_132","unstructured":"FDA (2020, September 01). FDA Approves Atezolizumab with Nab-Paclitaxel and Carboplatin for Metastatic NSCLC without EGFR\/ALK Aberrations; FDA: 2019, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-atezolizumab-nab-paclitaxel-and-carboplatin-metastatic-nsclc-without-egfralk."},{"key":"ref_133","unstructured":"FDA (2020, September 01). FDA Expands Pembrolizumab Indication for First-Line Treatment of NSCLC (TPS \u22651%); FDA: 2019, Available online: https:\/\/www.fda.gov\/drugs\/fda-expands-pembrolizumab-indication-first-line-treatment-nsclc-tps-1."},{"key":"ref_134","unstructured":"FDA (2020, October 01). FDA Approves Atezolizumab for First-Line Treatment of Metastatic NSCLC with High PD-L1 Expression; FDA: 2020, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-atezolizumab-first-line-treatment-metastatic-nsclc-high-pd-l1-expression."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_136","unstructured":"FDA (2020, September 01). FDA Approves Durvalumab for Extensive-Stage Small Cell Lung Cancer; FDA: 2020, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-durvalumab-extensive-stage-small-cell-lung-cancer#:~:text=FDA%20approves%20durvalumab%20for%20extensive-stage%20small%20cell%20lung,patients%20with%20extensive-stage%20small%20cell%20lung%20cancer%20(ES-SCLC)."},{"key":"ref_137","unstructured":"FDA (2020, October 01). FDA Grants Accelerated Approval to Lurbinectedin for Metastatic Small Cell Lung Cancer; FDA: 2020, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.21873\/invivo.11920","article-title":"Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping","volume":"34","author":"Hur","year":"2020","journal-title":"In Vivo"},{"key":"ref_139","unstructured":"FDA (2020, October 01). FDA Approves Ramucirumab Plus Erlotinib for First-Line Metastatic NSCLC; FDA: 2020, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-ramucirumab-plus-erlotinib-first-line-metastatic-nsclc."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ijc.30047","article-title":"NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors","volume":"139","author":"Yang","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_141","unstructured":"Takeda (2020). Takeda Announces U.S. FDA Breakthrough Therapy Designation for Mobocertinib (TAK-788) for the Treatment of NSCLC Patients with EGFR Exon 20 Insertion Mutations, Takeda."},{"key":"ref_142","unstructured":"NIH (2020, August 01). Liquid BIopsies in Patients Presenting Non-small Cell Lung Cancer (LIBIL); NIH: 2020, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02511288."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1517\/14728210802676278","article-title":"Emerging therapies for multiple myeloma","volume":"14","author":"Podar","year":"2009","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1158\/1078-0432.CCR-16-0624","article-title":"Multiple Myeloma: Multiplying Therapies","volume":"22","author":"Bates","year":"2016","journal-title":"J. Clin. Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/leu.2010.313","article-title":"Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and\/or transplant ineligible patients with multiple myeloma: A meta-analysis","volume":"25","author":"Kapoor","year":"2011","journal-title":"Leukemia"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.currproblcancer.2009.01.001","article-title":"Multiple myeloma","volume":"33","author":"Rajkumar","year":"2009","journal-title":"Curr. Probl. Cancer"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1038\/bcj.2015.92","article-title":"Interpretation of cytogenetic results in multiple myeloma for clinical practice","volume":"5","author":"Rajan","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas\u2014Current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1182\/blood-2011-01-270140","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): Novel biological insights and development of early treatment strategies","volume":"117","author":"Korde","year":"2011","journal-title":"Blood"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ajh.24236","article-title":"Myeloma today: Disease definitions and treatment advances","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/abbs\/gmt142","article-title":"Mechanism of immunomodulatory drugs\u2019 action in the treatment of multiple myeloma","volume":"46","author":"Chang","year":"2013","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_155","unstructured":"FDA (2020, August 01). Lenalidomide (Revlimid); FDA: 2017, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/lenalidomide-revlimid."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Mogoll\u00f3n, P., D\u00edaz-Tejedor, A., Algar\u00edn, E.M., Pa\u00edno, T., Garayoa, M., and Ocio, E.M. (2019). Biological Background of Resistance to Current Standards of Care in Multiple Myeloma. Cells, 8.","DOI":"10.3390\/cells8111432"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/CMAR.S105163","article-title":"Update on the optimal use of bortezomib in the treatment of multiple myeloma","volume":"9","author":"Mohan","year":"2017","journal-title":"Cancer Manag. Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1038\/leu.2015.274","article-title":"Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma","volume":"29","author":"Cavo","year":"2015","journal-title":"Leukemia"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/leu.2015.80","article-title":"Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma","volume":"29","author":"Mai","year":"2015","journal-title":"Leukemia"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood-2018-99-112659","article-title":"Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma","volume":"132","author":"Hebraud","year":"2018","journal-title":"Blood"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_162","unstructured":"FDA (2020, August 01). Drug Trials Snapshot: FARYDAK (Panobinostat); FDA: 2015, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshot-farydak-panobinostat."},{"key":"ref_163","unstructured":"NIH (2020, September 01). Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma; NIH: 2020, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03256045."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Paul, B., Lipe, B., Ocio, E.M., and Usmani, S.Z. (2019). Induction Therapy for Newly Diagnosed Multiple Myeloma. Am. Soc. Clin. Oncol. Educ. Book, e176\u2013e186.","DOI":"10.1200\/EDBK_238527"},{"key":"ref_165","first-page":"542","article-title":"Elotuzumab: The First Monoclonal Antibody for the Treatment of Multiple Myeloma","volume":"7","author":"Fancher","year":"2016","journal-title":"J. Adv. Pr. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1158\/1078-0432.CCR-16-2870","article-title":"FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma","volume":"23","author":"Gormley","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1182\/blood-2018-99-116225","article-title":"Elotuzumab Plus Pomalidomide\/Dexamethasone for the Treatment of Relapsed\/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study","volume":"132","author":"Hori","year":"2018","journal-title":"Blood"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2017.35.15_suppl.8002","article-title":"An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma","volume":"35","author":"Laubach","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors","volume":"186","author":"Tai","year":"2011","journal-title":"J. Immunol."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Htut, T., Thein, K., Lawrie, A., Tighe, J., and Preston, G. (2020). Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials. eJHaem, 262\u2013266.","DOI":"10.1002\/jha2.46"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1007\/s12325-020-01247-8","article-title":"Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses","volume":"37","author":"Xu","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_172","unstructured":"FDA (2020, October 01). FDA Approves Daratumumab and Hyaluronidase-Fihj for Multiple Myeloma; FDA: 2020, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-daratumumab-and-hyaluronidase-fihj-multiple-myeloma."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Abdallah, N., and Kumar, S.K. (2019). Daratumumab in untreated newly diagnosed multiple myeloma. Adv. Hematol., 10.","DOI":"10.1177\/2040620719894871"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"TPS8609","DOI":"10.1200\/jco.2015.33.15_suppl.tps8609","article-title":"Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide\/dexamethasone or bortezomib\/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004 (Castor)","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_177","unstructured":"FDA (2020, August 01). FDA Approves Carfilzomib and Daratumumab with Dexamethasone for Multiple Myeloma; FDA: 2020, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-carfilzomib-and-daratumumab-dexamethasone-multiple-myeloma."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Moreno, L., P\u00e9rez, C., Zabaleta, A., Manrique, I., Alignani, D., Ajona, D., Blanco, L., Lasa, M., Maiso, P., and Rodriguez, I. (2019). The Mechanism Of Action Of The Anti-CD38 Monoclonal Antibody Isatuximab In Multiple Myelmoa. J. Clin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-18-1597"},{"key":"ref_179","unstructured":"FDA (2020, September 01). FDA Approves Isatuximab-Irfc for Multiple Myeloma; FDA: 2020, Available online: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-approves-isatuximab-irfc-multiple-myeloma#:~:text=On%20March%202%2C%202020%2C%20the,lenalidomide%20and%20a%20proteasome%20inhibitor."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"TPS8055","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS8055","article-title":"Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM)","volume":"36","author":"Orlowski","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2352-3026(19)30249-2","article-title":"MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: A first-in-human, multicentre, phase 1-2a trial","volume":"7","author":"Raab","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/14656566.2019.1707184","article-title":"Selinexor for the treatment of multiple myeloma","volume":"21","author":"Podar","year":"2020","journal-title":"Expert Opin. Pharm."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1158\/1078-0432.CCR-18-3728","article-title":"A Phase Ib\/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenstr\u00f6m Macroglobulinemia","volume":"25","author":"Ghobrial","year":"2019","journal-title":"J. Clin. Cancer Res."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/bjh.14987","article-title":"A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): Final study results","volume":"180","author":"Spencer","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_185","unstructured":"NIH (2020, September 01). National Center for Biotechnology Information. PubChem Database. Melphalan Flufenamide, CID=9935639; NIH: 2020, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Melphalan-flufenamide."},{"key":"ref_186","unstructured":"Oncopeptides (2020, September 01). Melflufen\u2013Investigational Drug; Oncopeptides: 2020. Available online: https:\/\/www.oncopeptides.com\/en\/innovation\/investigational-drug."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1200\/JCO.2020.38.15_suppl.8509","article-title":"Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed\/refractory multiple myeloma","volume":"38","author":"Kumar","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_188","unstructured":"AbbVie (2019). AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the t(11;14) Genetic Abnormality, PRNewswire."},{"key":"ref_189","unstructured":"FDA (2020, August 01). FDA Warns about the Risks Associated with the Investigational use of Venclexta in Multiple Myeloma; FDA: 2019, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-risks-associated-investigational-use-venclexta-multiple-myeloma#:~:text=Venclexta%20is%20safe%20and%20effective,these%20trials%20after%20they%20reconsent."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/d41573-019-00105-9","article-title":"The BCMA bonanza","volume":"18","author":"Mullard","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti\u2013B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"ref_193","unstructured":"FDA (2020, August 01). FDA Granted Accelerated Approval to Belantamab Mafodotin-Blmf for Multiple Myeloma; FDA: 2020, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody\u2013drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: An update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_195","unstructured":"GSK (2020, September 01). GSK Announces Further Positive Data from DREAMM-1 Study of anti-BCMA Antibody-Drug Conjugate in Patients with Relapsed\/Refractory Multiple Myeloma; GSK: 2019. Available online: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-announces-further-positive-data-from-dreamm-1-study-of-anti-bcma-antibody-drug-conjugate\/."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood-2019-127163","article-title":"Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma","volume":"134","author":"Xing","year":"2019","journal-title":"Blood"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1182\/blood.V126.23.2999.2999","article-title":"BI 836909, a Novel Bispecific T Cell Engager for the Treatment of Multiple Myeloma Induces Highly Specific and Efficacious Lysis of Multiple Myeloma Cells in Vitro and Shows Anti-Tumor Activity in Vivo","volume":"126","author":"Hipp","year":"2015","journal-title":"Blood"},{"key":"ref_198","first-page":"5389","article-title":"Generation of Half-Life Extended Anti-BCMA Bite\u00ae Antibody Construct Compatible with Once-Weekly Dosing for Treatment of Multiple Myeloma (MM)","volume":"130","author":"Goyos","year":"2017","journal-title":"Blood"},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Usmani, S.Z., Mateos, M.V., Nahi, H., Krishnan, A.Y., van de Donk, N.W., San Miguel, J., Miguel, J.S., Oriol, A., Rosi\u00f1ol, L., and Chari, A. (2020). Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed\/refractory multiple myeloma (R\/R MM). J. Clin. Oncol.","DOI":"10.1200\/JCO.2020.38.15_suppl.100"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fimmu.2020.00501","article-title":"Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions","volume":"11","author":"Caraccio","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_201","unstructured":"BMS (2019). Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma. Study Met Its Primary Endpoint and Key Secondary Endpoint, Demonstrating Deep and Durable Responses in a Heavily Pre-Treated Multiple Myeloma Patient Population, Bristol-Myers Squibb Company (NYSE:BMY)."},{"key":"ref_202","unstructured":"BMS (2019). Bluebird Bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed\/Refractory Multiple Myeloma at 61st ASH Annual Meeting and Exposition, BMS."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"8505","DOI":"10.1200\/JCO.2020.38.15_suppl.8505","article-title":"Update of CARTITUDE-1: A phase Ib\/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed\/refractory multiple myeloma","volume":"38","author":"Berdeja","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/blood-2019-124345","article-title":"CC-92480, a Novel Cereblon E3 Ligase Modulator, Is Synergistic with Dexamethasone, Bortezomib, and Daratumumab in Multiple Myeloma","volume":"134","author":"Wong","year":"2019","journal-title":"Blood"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1182\/blood-2018-99-113383","article-title":"Iberdomide (CC-220) Has Synergistic Anti-Tumor and Immunostimulatory Activity Against Multiple Myeloma in Combination with Both Bortezomib and Dexamethasone, or in Combination with Daratumumab in Vitro","volume":"132","author":"Amatangelo","year":"2018","journal-title":"Blood"},{"key":"ref_209","unstructured":"NIH (2020, September 01). A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination with Other Treatments in Subjects with Multiple Myeloma; NIH: 2020, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02773030."},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Pestana, R.C., Sen, S., Hobbs, B.P., and Hong, D.S. (2020). Histology-agnostic drug development - Considering issues beyond the tissue. Nat. Rev. Clin. Oncol.","DOI":"10.1038\/s41571-020-0384-0"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrd.2018.6","article-title":"Tissue-agnostic cancer drug pipeline grows, despite doubts","volume":"17","author":"Garber","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2217\/fon-2019-0534","article-title":"Systematic review of neurotrophic tropomyosin-related kinase inhibition as a tumor-agnostic management strategy","volume":"16","author":"Chu","year":"2020","journal-title":"Future Oncol."},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Li, I.W., Krishnamurthy, N., Wei, G., and Li, G. (2020). Opportunities and challenges in developing tissue-agnostic anti-cancer drugs. J. Cancer Metastasis Treat, 6.","DOI":"10.20517\/2394-4722.2020.27"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"103109","DOI":"10.1016\/j.critrevonc.2020.103109","article-title":"ctDNA as a cancer biomarker: A broad overview","volume":"155","author":"Pessoa","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","article-title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"Liu","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.annonc.2020.05.028","article-title":"A multi-cancer detection test: Focus on the positive predictive value","volume":"31","author":"Fiala","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.annonc.2020.04.013","article-title":"Comment on \u2018Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA\u2019 by M. C. Liu et al","volume":"31","author":"Taylor","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/s41467-020-17316-z","article-title":"Non-invasive early detection of cancer four years before conventional diagnosis using a blood test","volume":"11","author":"Chen","year":"2020","journal-title":"Nat. Commun."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/4\/2008\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:25:34Z","timestamp":1760160334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/4\/2008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":219,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["ijms22042008"],"URL":"https:\/\/doi.org\/10.3390\/ijms22042008","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]}}}